drugset
drugset / Trial / NCT06730659

A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors

NCT06730659 ↗

Phase 1 Recruiting 36 enrolled Tianjin Medical University Cancer Institute and Hospital Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive advanced solid tumors.

Timeline

Start
2024-04-19
Primary completion
2027-04-18
Completion
2039-04-18

Drugs

EvaluationDrugModalityDoseRoute
Subject CHT101 Cell therapy — Intravenous

Indications

refractory malignant neoplasm